<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-99008</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Kt as control and follow-up of the dose at a hemodialysis unit</dc:title>
<dc:description xml:lang="en">To ensure our patients are receiving an adequate dose in every dialysis session there must be a target to achieve this in the short or medium term. The incorporation during the last years of the ionic dialysance (ID) in the monitors, has provided monitoring of the dialysis dose in real time and in every dialysis session. Lowrie y cols., recommend monitoring the dose with Kt, recommending at least 40 L in women and 45 L in men or individualizing the dose according to the body surface area. The target of this study was to monitor the dose with Kt in every dialysis session for 3 months,and to compare it with the monthly blood test. 51 patients (58%of our hemodialysis unit), 32 men and 19 women, 60.7 ± 14 years old, in the hemodialysis program me for 37.7 ± 52 months, were dialysed with a monitor with IC. The etiology of their chronic renalfailure was: 3 tubulo-interstitial nephropathy, 9 glomerulonephritis,12 vascular disease, 7 polycystic kidney disease, 7 diabetic nephropathy and 13 unknown. 1,606 sessions were analysed during a 3 month period. Every patient was treated with the usual parameters of dialysis with 2.1 m2 cellulose diacetate (33.3%), 1.9m2 polisulfone (33.3%) or 1.8 m2 helixone, dialysis time of 263 ±32 minutes, blood flow of 405 ± 66, with dialysate flow of 712 ±138 and body weight of 66.7 ± 14 kg. ITo ensure our patients are receiving an adequate dose in every dialysis session there must be a target to achieve this in the short or medium term. The incorporation during the last years of the ionic dialysance (ID) in the monitors, has provided monitoring of the dialysis dose in real time and in every dialysis session. Lowrie y cols., recommend monitoring the dose with Kt, recommending at least 40 L in women and 45 L in men or individualizing the dose according to the body surface area. The target of this study was to monitor the dose with Kt in every dialysis session for 3 months, and to compare it with the monthly blood test. 51 patients (58% of our hemodialysis unit), 32 men and 19 women, 60.7 ± 14 years old, in the hemodialysis programme for 37.7 ± 52 months, were dialysed with a monitor with IC. The etiology of their chronic renal failure was: 3 tubulo-interstitial nephropathy, 9 glomerulonephritis, 12 vascular disease, 7 polycystic kidney disease, 7 diabetic nephropathy and 13 unknown. 1,606 sessions were analysed during a 3 month period. Every patient was treated with the usual parameters of dialysis with 2.1 m2 cellulose diacetate (33.3%), 1.9 m2 polisulfone (33.3%) or 1.8 m2 helixone, dialysis time of 263 ± 32 minutes, blood flow of 405 ± 66, with dialysate flow of 712 ± 138 and body weight of 66.7 ± 14 kg. Initial ID, final ID and Kt were measured in each session. URR and Kt/V were obtained by means of a monthly blood test. The initial ID was 232 ± 41 ml/min, the final ID was 197 ± 44 ml/min, the mean of Kt determinations was 56.6 ± 14 L, the mean of Kt/V was 1.98 ± 0.5 and the mean of URR was 79.2 ± 7%. Although all patients were treated with a minimum recommended dose of Kt/V and URR when we used the Kt according to gender, we observed that 31% of patients do not get the minimum dose prescribed (48.1 ± 2.4 L), 34.4% of the men and 26.3% of the women. If we use the Kt individualized for the body surface area, we observe that 43.1% of the patients do not get the minimum dose prescribed with 4.6 ± 3.4 L less than the dose prescribed. We conclude that the monitoring of dialysis dose with the Kt provides a better discrimination detecting that between 30 and 40% of the patients perhaps do not get an adequate dose for their gender or body surface areanitial ID, final ID and Kt (..) (AU)</dc:description>
<dc:creator>Collado, S</dc:creator>
<dc:creator>Maduell, F</dc:creator>
<dc:creator>Blasco, M</dc:creator>
<dc:creator>Arias, M</dc:creator>
<dc:creator>Cases, A</dc:creator>
<dc:creator>Fernández, A</dc:creator>
<dc:creator>Serra, N</dc:creator>
<dc:creator>Campistol, JM</dc:creator>
<dc:creator>Carrera, M</dc:creator>
<dc:creator>Vera, M</dc:creator>
<dc:creator>Bergadá, E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Asegurar que el paciente recibe la dosis adecuada en cada sesión de diálisis debe ser un objetivo a conseguir a corto o medio plazo. La incorporación de la dialisancia iónica (DI) en los monitores durante los últimos años ha permitido monitorizar la dosis de hemodiálisis en tiempo real y en cada sesión. Lowrie y cols., recomiendan el seguimiento de la dosis con el Kt, recomendando un mínimo de 40 L en mujeres y 45 en hombres o individualizar la dosis por área de superficie corporal. El objetivo del presente estudio era hacer un seguimiento de la dosis con el Kt en cada sesión durante 3 meses, y comparar con la analítica mensual habitual. 51 pacientes (58% de la Unidad de hemodiálisis), 32 varones y 19 mujeres, de 60,7 ± 14 años de edad, en programa de hemodiálisis durante 37,7 ± 52 meses, se dializaron con monitor con DI de forma rutinaria. La etiología de su IRC era de 3 NTI, 9 GNC, 12 nefroangiosclerosis, 7 poliquistosis renal, 7 diabetes mellitus y 13 no filiada. Se analizaron 1.606 sesiones durante 3 meses. Cada paciente recibió la pauta habitual de HD, con dializadores de diacetato de celulosa de 2,1 m2 (33,3%), polisulfona de 1,9 m2 (33,3%) y helixona de 1,8 m2, con duración de 263 ± 32 minutos, con un flujo sanguíneo de 405 ± 66, con flujo baño a 712 ± 138 ml/min, peso seco de 66,7 ± 14 kg. Se valoró la DI inicial, la DI final y el Kt en cada sesión y el PRU y el Kt/V mediante la analítica mensual. La DI inicial fue de 232 ± 41 ml/min, la DI final de 197 ± 44 ml/min, la dosis media de Kt fue de 56,6 ± 14 L, el Kt/V medio de 1,98 ± 0,5 y el PRU de 79,2 ± 7%. Todos los pacientes recibieron una dosis mínima de Kt/V y PRU de 1,3 y 70%, respectivamente. No obstante, si utilizamos el Kt según el sexo, observamos que el 31% de los pacientes no alcanzaban la dosis mínima prescrita (48,1 ± 2,4 L), 34,4% de los hombres y el 26,3% de las mujeres. Si utilizamos el Kt individualizado por su superficie corporal, (49,1 ± 4 L), observamos que el 43.1% de los pacientes no alcanzaban la dosis mínima prescrita, con 4,6 ± 3,4 L menos de dosis. Concluimos que el seguimiento de la dosis de diálisis con el Kt, permite una mejor discriminación de la adecuación de diálisis, identificando entre el 30 y el 40% de pacientes que quizá no alcanzasen una dosis adecuada para su género o para su superficie corporal (AU)</dc:description>
<dc:source>Nefrologia;28(1): 43-47, ene.-feb. 2008. ilus, tab</dc:source>
<dc:identifier>ibc-99008</dc:identifier>
<dc:title xml:lang="es">Kt como control y seguimiento de la dosis en una unidad de hemodiálisis</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d52415^s22073</dc:subject>
<dc:subject>^d50495^s22067</dc:subject>
<dc:subject>^d29407^s22045</dc:subject>
<dc:subject>^d14907^s22002</dc:subject>
<dc:subject>^d23663^s22000</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9183^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>200802</dc:date>
</metadata>
</record>
</ibecs-document>
